Pfizer Inc. announced the presentation of real-world evidence that demonstrated an associated benefit for patients treated with IBRANCE (palbociclib) in combination with an aromatase inhibitor (AI), as compared to AI alone, in the first-line setting, at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 Congress, according to a news release.
This retrospective cohort study is a large comparative effectiveness study of 2,888 hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) patients evaluating IBRANCE in combination with AI compared to AI alone and demonstrated an associated improved overall survival (OS) in post-menopausal women and in men with HR+, HER2- mBC treated in routine clinical practice in the United States.
After balancing for baseline demographic and clinical characteristics, median OS was significantly longer in the palbociclib group versus AI group of 49.1 vs 43.2 months. Real-world median progression-free survival was 19.3 versus 13.9 months, respectively in this observational, retrospective real-world analysis. These findings represent a 24% reduction in the risk of death and a 30% reduction in the risk of progression. Safety data were not collected as part of this analysis.
“I’ve witnessed first-hand the positive impact of palbociclib in combination with endocrine therapy in patients with HR+, HER2- metastatic breast cancer,” said Hope S. Rugo, MD, lead researcher and Professor of Medicine at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. “It is encouraging to see associated improved overall survival extend beyond my own practice in the real-world setting, and these additional results, along with clinical trial data, may help healthcare providers make more fully informed treatment decisions for their patients.”
The poster, “Overall Survival with First-Line Palbociclib Plus an Aromatase Inhibitor (AI) vs AI in Metastatic Breast Cancer: A Large Real-World Database Analysis” is on display at the ESMO Breast Cancer 2022 Congress on May 4, 2022, and can be accessed starting May 3, 2022, to those registered for the Congress.
